Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 5/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10865018 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL9687886 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL10867509 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL10867800 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL10866687 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL10866068 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL10866483 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL10868195 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL10868221 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 | |
| SCHEMBL9688998 | 1.00 | LPAR3 (0.42) | LPAR3LPAR1LPAR2NAAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0175591-A2 | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device | CANON KABUSHIKI KAISHA (JP) | 1986-03-26 | — | — | EP | claimed |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | EPITRACKER INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | Epitracker, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3934639-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-5167857-A | Optically active, optical modulation | CANON KABUSHIKI KAISHA (JP) | 1992-12-01 | — | — | US | disclosed |
| US-5114613-A | High-speed responsive, stable films; controlling the mesomorphic state and temperature | CANON KABUSHIKI KAISHA (JP) | 1992-05-19 | — | — | US | disclosed |
| EP-0175591-B1 | LACTIC ACID DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING SAME AND LIQUID CRYSTAL DEVICE | CANON KABUSHIKI KAISHA (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4882085-A | Lactic acid derivative and liquid crystal composition containing same | CANON KABUSHIKI KAISHA (JP) | 1989-11-21 | — | — | US | disclosed |
| US-4775223-A | DISPLAY DEVICE | CANON KABUSHIKI KAISHA (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0175591-A2 | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device | CANON KABUSHIKI KAISHA (JP) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | LPAR3 1401/4885LPAR1 670/4885LPAR2 865/4885 |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | SCD, FABP7, ELOVL1 | LPAR3 336/4885LPAR1 334/4885LPAR2 314/4885 |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | LPAR3 1401/4885LPAR1 670/4885LPAR2 865/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | LPAR3 1401/4885LPAR1 670/4885LPAR2 865/4885 |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | CNR1, CNR2, FFAR1 | LPAR3 244/4885LPAR1 211/4885LPAR2 250/4885 |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | SCD, FABP7, ELOVL1 | LPAR3 336/4885LPAR1 334/4885LPAR2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.